RATIONALE: Analysis of the age of onset in heritable pulmonary arterial hypertension (HPAH) has led to the hypothesis that genetic anticipation causes younger age of onset and death in subsequent generations. With accrual of pedigree data over multiple decades, we retested this hypothesis using analyses that eliminate the truncation of data that exists with shorter duration of follow-up. OBJECTIVES: To analyze the pedigrees of families with mutations in bone morphogenetic protein receptor type 2 (BMPR2), afflicted in two or more generations with HPAH, eliminating time truncation bias by including families for whom we have at least 57 years of data. METHODS: We analyzed 355 individuals with BMPR2 mutations from 53 families in the Vanderbilt Pulmonary Hypertension Registry. We compared age at diagnosis or death in affected individuals (n = 249) by generation within families with multigenerational disease. We performed linear mixed effects models and we limited time-truncation bias by restricting date of birth to before 1955. This allowed for 57 years of follow-up (1955-2012) for mutation carriers to develop disease. We also conducted Kaplan-Meier analysis to include currently unaffected mutation carriers (n = 106). MEASUREMENTS AND MAIN RESULTS: Differences in age at diagnosis by generation were found in a biased analysis that included all birth years to the present, but this finding was eliminated when the 57-year observation limit was imposed. By Kaplan-Meier analysis, inclusion of currently unaffected mutation carriers strengthens the observation that bias of ascertainment exists when recent generations are included. CONCLUSIONS: Genetic anticipation is likely an artifact of incomplete time of observation of kindreds with HPAH due to BMPR2 mutations.
RATIONALE: Analysis of the age of onset in heritable pulmonary arterial hypertension (HPAH) has led to the hypothesis that genetic anticipation causes younger age of onset and death in subsequent generations. With accrual of pedigree data over multiple decades, we retested this hypothesis using analyses that eliminate the truncation of data that exists with shorter duration of follow-up. OBJECTIVES: To analyze the pedigrees of families with mutations in bone morphogenetic protein receptor type 2 (BMPR2), afflicted in two or more generations with HPAH, eliminating time truncation bias by including families for whom we have at least 57 years of data. METHODS: We analyzed 355 individuals with BMPR2 mutations from 53 families in the Vanderbilt Pulmonary Hypertension Registry. We compared age at diagnosis or death in affected individuals (n = 249) by generation within families with multigenerational disease. We performed linear mixed effects models and we limited time-truncation bias by restricting date of birth to before 1955. This allowed for 57 years of follow-up (1955-2012) for mutation carriers to develop disease. We also conducted Kaplan-Meier analysis to include currently unaffected mutation carriers (n = 106). MEASUREMENTS AND MAIN RESULTS: Differences in age at diagnosis by generation were found in a biased analysis that included all birth years to the present, but this finding was eliminated when the 57-year observation limit was imposed. By Kaplan-Meier analysis, inclusion of currently unaffected mutation carriers strengthens the observation that bias of ascertainment exists when recent generations are included. CONCLUSIONS: Genetic anticipation is likely an artifact of incomplete time of observation of kindreds with HPAH due to BMPR2 mutations.
Authors: J E Loyd; M G Butler; T M Foroud; P M Conneally; J A Phillips; J H Newman Journal: Am J Respir Crit Care Med Date: 1995-07 Impact factor: 21.405
Authors: S Rich; D R Dantzker; S M Ayres; E H Bergofsky; B H Brundage; K M Detre; A P Fishman; R M Goldring; B M Groves; S K Koerner Journal: Ann Intern Med Date: 1987-08 Impact factor: 25.391
Authors: Xinping Chen; Eric D Austin; Megha Talati; Joshua P Fessel; Eric H Farber-Eger; Evan L Brittain; Anna R Hemnes; James E Loyd; James West Journal: Eur Respir J Date: 2017-08-03 Impact factor: 16.671
Authors: Neil J Kelly; Josiah E Radder; Jeffrey J Baust; Christine L Burton; Yen-Chun Lai; Karin C Potoka; Brittani A Agostini; John P Wood; Timothy N Bachman; Rebecca R Vanderpool; Nadine Dandachi; Adriana S Leme; Alyssa D Gregory; Alison Morris; Ana L Mora; Mark T Gladwin; Steven D Shapiro Journal: Am J Respir Cell Mol Biol Date: 2017-04 Impact factor: 6.914
Authors: Ling Yan; Joy D Cogan; Lora K Hedges; Bethany Nunley; Rizwan Hamid; Eric D Austin Journal: Am J Respir Crit Care Med Date: 2018-12-15 Impact factor: 21.405
Authors: Wen Tian; Xinguo Jiang; Yon K Sung; Eric Shuffle; Ting-Hsuan Wu; Peter N Kao; Allen B Tu; Peter Dorfmüller; Aiqin Cao; Lingli Wang; Gongyong Peng; Yesl Kim; Patrick Zhang; James Chappell; Shravani Pasupneti; Petra Dahms; Peter Maguire; Hassan Chaib; Roham Zamanian; Marc Peters-Golden; Michael P Snyder; Norbert F Voelkel; Marc Humbert; Marlene Rabinovitch; Mark R Nicolls Journal: Circulation Date: 2019-08-29 Impact factor: 29.690
Authors: Chiara Federici; Kylie M Drake; Christina M Rigelsky; Lauren N McNelly; Sirena L Meade; Suzy A A Comhair; Serpil C Erzurum; Micheala A Aldred Journal: Am J Respir Crit Care Med Date: 2015-07-15 Impact factor: 21.405